Novel human-derived RET fusion NSCLC cell lines have heterogeneous responses to RET inhibitors and differential regulation of downstream signaling

Data Supplement

• Data Supplement -

  Supplemental Figure 1 - A. Representative phase contrast images from InCucyte of CUTO22, CUTO32, CUTO42 and LC-2/Ad cells under untreated conditions show different cellular morphologies.

  Supplemental Figure 2 - RET inhibitors rapidly decrease RET activation and is sustained for up to 24 hours.

  Supplemental Figure 3 - CUTO32 cells treated with indicated concentrations of ponatinib, RXDX-105 or BLU-667 for 2 hours.

  Supplemental Figure 4 - . CUTO32 cells are sensitive to PLK1 and Aurora kinase inhibitors in drug screen.

  Supplemental Figure 5 - Normalized expression in counts per million (CPM) of selected genes from RNA sequencing.

  Supplemental Figure 6 - Co-inhibition of MET does not sensitize RET+ cells to RET inhibitors.

  Supplemental Figure 7 - Average mouse weight measurements for xenograft experiments.